High-Purity Reagents for Molecular Glue and PROTAC Development — Sequence-verified CRBN wild-type and resistance mutants (D390V, R419G, G416E), neosubstrate proteins (IKZF1/3), and lentiviral systems for ternary complex assays.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CRBN-targeted protein degradation. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (WT) | CRBN Full-Length Recombinant Protein High purity (>95%), Endotoxin <1EU/µg. Sequence Verified. HEK293 or E. coli expressed. |
View CRBN Products |
| Antigen (Mutants) | CRBN Resistance Mutant Panel (D390V, R419G, G416E) Theoretical MW confirmed by Mass Spec. For resistance mechanism studies. |
View CRBN Products |
| Gene Delivery | CRBN Lentivirus Premade Particles WT and mutant ORF for stable cell line construction in hematologic cell models. |
View CRBN Products |
| Neosubstrate | IKZF1 (Ikaros) Recombinant Protein High purity (>95%). For ternary complex formation assays with CRBN molecular glues. |
View IKZF1 Products |
| Neosubstrate | IKZF3 (Aiolos) Recombinant Protein Sequence Verified. Critical for IMiD mechanism studies. |
View IKZF3 Products |
| Complex Component | DDB1 Recombinant Protein Part of CRL4^CRBN E3 ligase complex. For holo-complex assembly studies. |
View DDB1 Products |
| Benchmark Ab | Anti-CRBN Monoclonal Antibody (Sequence Verified) For Western Blot, IP, and cellular CRBN quantification. |
View CRBN Products |
| Validator | CRBN siRNA Set (3 unique sequences) For knockdown verification and specificity controls. |
View CRBN Products |
| Related Target | VHL Primary alternative E3 ligase for PROTAC development. |
View VHL Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Ternary Complex Formation (CRBN-Drug-Neosubstrate) | Purified CRBN + IKZF1/3 proteins with verified binding domains. Compatible with AlphaScreen/FP assays. |
| Resistance Mutation Screening (Clinical relapses) | CRBN D390V, R419G, G416E mutant proteins available. Sequence-verified against patient-derived mutations. |
| Cross-species Translation (Cyno/Mouse) | Human/Mouse/Cyno CRBN ortholog proteins with >95% purity for preclinical safety profiling. |
| CRL4 Complex Assembly | DDB1 and CUL4A proteins available for full E3 ligase reconstitution studies. |
| False Positives / Off-target Binding | Validated CRBN siRNA and negative control mutants (binding-deficient) included for specificity confirmation. |
| Assay Interference | High Purity (>95%) strictly verified by SEC-HPLC and Mass Spectrometry. |
Live CRBN R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for next-generation CRBN modulators is shifting from traditional immunomodulatory imide drugs (IMiDs) to targeted molecular glue degraders and PROTACs. As first-generation agents (lenalidomide, pomalidomide) face increasing resistance via CRBN mutations (D390V, R419G), the industry is pivoting toward:
- Mutation-agnostic glues that retain efficacy against resistance alleles
- Neosubstrate-selective degraders that spare SALL4 (avoiding teratogenicity) while efficiently degrading IKZF1/3
- Non-IMiD CRBN binders with novel chemotypes for expanded target scope
The next wave of R&D focuses on rational glue design rather than serendipitous discovery, requiring precise biophysical characterization of ternary complexes. Expansion into immunology and neurodegenerative indications is also emerging.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Molecular Glue (IKZF1/3) | BMS/Celgene, Novartis, Monte Rosa | Multiple Myeloma, NHL | Ternary Complex Assay (CRBN + IKZF1/3 purified proteins) |
| PROTACs | Arvinas, C4 Therapeutics, Nurix | Solid Tumors, Metastatic Cancers | Cell-based Degradation (CRBN lentivirus for stable lines) |
| Novel Chemotype Glues | Proxygen, Stingray Therapeutics | Autoimmune Diseases | Resistance Mutant Panel (D390V, R419G screening) |
| Allosteric Modulators | Various Biotech | Myelodysplastic Syndromes | Thermal Shift Assay (High-purity WT CRBN) |